July 16, 2012 -- Lee’s Pharmaceutical of Hong Kong has bought the China rights to a novel clinical-stage peptide from RegeneRx Biopharma. Thymosin beta 4 (Tß4) is being developed by for tissue and organ protection, repair and regeneration. Its three formulations target very different indications: dry eye, cardiovascular/nervous system disorders, and skin disease/chronic wounds. More details....
Stock Symbols: (HK: 950) (OTCBB: RGRX)
